Different duration of BTKi plus BCL2i combinations in relapsed CLL. This figure shows the treatment duration of different published BTKi plus BCL2i (with or without obinutuzumab) combinations in relapsed CLL. The dark part of the bars indicates the minimal treatment duration, and the light part indicates the optional, MRD-guided prolongation of treatment. The table lists key demographic and outcome data from the shown trials. A, acalabrutinib; I, ibrutinib; NA, data not available; Obi, obinutuzumab; V, venetoclax; Z, zanubrutinib. References of depicted trials: Ohio State10; CLL2-BAAG6; CLL2-BZAG7; CLARITY8; VISION9; SAKK 34/171.
